In:
International Journal of Cancer, Wiley, Vol. 139, No. 6 ( 2016-09-15), p. 1297-1302
Abstract:
What's new? Accumulating clinical and experimental evidence indicates that the T‐cell modulatory properties of CD5 might play a role in the antitumor immune response by acting as a putative immune regulator checkpoint. Here, the authors examined the association between CD5 allelic variations at SNPs rs2229177 and rs2241002 and clinical outcome of malignant melanoma in two independent cohorts. They found that CD5 functional variants influence melanoma outcome, illustrating the contribution of the genetic variability of the host's immune response on patient survival prospects. This study supports the CD5 immune checkpoint as a new target for the improvement and development of new cancer immunotherapies.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8